

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://gov.uk/mhra)

## Decision Cover Letter

### Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-101189-PIP01-23)  
MHRA-101189-PIP01-23-M01

### Scope of the Application

#### Active Substance(s)

Zasocitinib

#### Condition(s)

Treatment of psoriasis

#### Pharmaceutical Form(s)

Film-coated tablet Age-appropriate oral formulation

#### Route(s) of Administration

ORAL USE

#### Name / Corporate name of the PIP applicant

Takeda UK Limited

#### Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Takeda UK Limited submitted to the licensing authority on 26/08/2025 21:06 BST an application for a

The procedure started on 04/11/2025 10:20 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-101189-PIP01-23-M01

Of 22/12/2025 14:46 GMT

On the adopted decision for Zasocitinib (MHRA-101189-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a for Zasocitinib , Film-coated tablet Age-appropriate oral formulation , ORAL USE .

This decision is addressed to Takeda UK Limited, 1 Kingdom Street, London, UNITED KINGDOM, W2 6BD

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of psoriasis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth less than 6 years Pharmaceutical form(s): Film-coated tablet Age-appropriate oral formulation Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of psoriasis

## 2.2 Indication(s) targeted by the PIP:

Treatment of moderate to severe chronic plaque psoriasis

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years of age to less than 18 years of age

## 2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate oral formulation

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an oral age-appropriate formulation for use in children aged from 6 years to less than 18 years.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 2 Two-part double-blind, randomised, placebo-controlled study to evaluate the pharmacokinetics, safety and efficacy of zasocitinib in children from 6 years to less than 18 years of age with moderate to severe plaque psoriasis (Part A), with an open label non-comparative cohort (Part B) to evaluate pharmacokinetics of zasocitinib and acceptability/palatability of the age-appropriate formulation developed in PIP study 1 in children from 6 years to less than 12 years of age
Extrapolation, Modeling & Simulation Studies	1	Study 3 Modelling and simulation analyses to determine the zasocitinib paediatric dose(s) to be used in children from 6 years to less than 12 years of age with moderate to severe plaque psoriasis.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

## 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	31/05/2030
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes